More News

Topline results from metastatic breast cancer phase 3 trial

Jim Cornall -
BioNTech SE and DualityBiologics (Suzhou) Co., Ltd. have announced that the DYNASTY-Breast02 global phase 3 clinical trial met its...

Updated prostate cancer results show anti-tumour activity

Jim Cornall -
AdvanCell has announced updated results from the TheraPb phase 1 clinical trial evaluating ADVC001, an investigational lead-212 PSMA-targeted alpha...

Gesynta Pharma continues endometriosis work

Jim Cornall -
Gesynta Pharma AB has completed enrolment in NOVA, its phase 2 clinical proof-of-concept and dose-finding trial. With 213 patients...

First-in-human circular RNA therapy for radiation-induced xerostomia

Jim Cornall -
RiboX Therapeutics has announced the publication of a peer-reviewed Research Letter in The New England Journal of Medicine (NEJM)...

Data show unresectable patients becoming eligible for surgery

Jim Cornall -
Brenus Pharma has announced first data from the phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were...

Personalised cancer vaccine with immunotherapy reduces melanoma recurrence after surgery

Jim Cornall -
Adding a personalised mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or...

AI drug choices may cost millions

Jim Cornall -
Large language models (LLMs), such as ChatGPT and Claude, are increasingly being used to provide health information to the...

Researchers reprogramme pancreatic cancer tumour microenvironment

Jim Cornall -
Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers. One reason for its resistance to therapy is...

Base to Base biotech podcast 81: Breakthrough in shrinking tumours and restoring mitochondrial metabolism to address obesity

Jim Cornall -
This week, we talk about mitochondria and obesity with Jon Rees, co-founder and CEO of MitoRx Therapeutics, and also...

New bacteria discovered in DNA samples from prostate cancer patients

admin -
University of East Anglia researchers have discovered the genetic blueprints of 18 new bacterial species collected from prostate cancer...

Estuary Biotherapeutics launches with $103m to develop gene therapies for kidney disease

Jim Cornall -
Estuary Biotherapeutics, Inc. has launched with $103m in total committed financing. The financing will support advancement of the company’s two...

Data show reduction in skin epigenetic age and systemic inflammatory biomarkers

Jim Cornall -
Rubedo Life Sciences has revealed new phase 1b clinical findings for RLS-1496, its lead investigational GPX4 modulator. In patients with...

Blood proteins may offer clues to gut health in coeliac disease

Jim Cornall -
Coeliac disease is an autoimmune condition in which the immune system reacts adversely to gluten. Eating gluten causes inflammation...

IMU and UK Biobank to generate world’s most detailed picture of the human immune system

Jim Cornall -
IMU Biosciences has announced a collaboration with UK Biobank to generate large-scale multi-omic immune profiling data from 80,000 blood...

Positive results from schizophrenia study

Jim Cornall -
Tortugas Neuroscience has announced positive phase 2b trial results for obuprazine (TRTL-107), the company’s investigational treatment for schizophrenia. Results from...

Jyong Biotech looks to Texas

Jim Cornall -
Jyong Biotech Ltd. says it plans to establish a potential new manufacturing facility and US operations centre in Texas. The...

New AI tool helps diagnose Ewing sarcoma

Jim Cornall -
A team from the Universitat Politècnica de València (UPV) and the University of Valencia (UV) has developed and validated...

Antibody shows attacking tumour environment also kills cancer cells

Jim Cornall -
Basque biopharmaceutical company Oncomatryx has taken part, together with German research institutions, in a study showing in patient tumour...

FDA clearance leads to influenza trial

Jim Cornall -
Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) has announced that the U.S. Food and Drug Administration (FDA) has granted its...

Plasmonic coating paves way for rapid sepsis diagnosis

Jim Cornall -
A research team has developed a label-free surface-enhanced Raman scattering (SERS) analysis technology that rapidly detects extremely low concentrations...

Mentara Therapeutics launches to tackle dyskinesia

Jim Cornall -
Mentara Therapeutics, a new neuropsychiatry company backed by SPRIM Global Investments, has launched with the acquisition of EM-221, now...